Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Male Hypogonadism Market Growth in 2025?

The market size for male hypogonadism has seen a substantial growth lately. The expansion from $3.75 billion in 2024 to $3.99 billion in 2025 will occur at a compound annual growth rate (CAGR) of 6.3%. Increments in the past period can be associated with factors such as an aging population, heightened awareness and diagnosis, lifestyle aspects, chronic diseases, and the behavior of seeking treatment.

What Is the Forecast for the Male Hypogonadism Market Size Through 2029?

The market for male hypogonadism is anticipated to experience substantial growth in the forthcoming years. It’s projected that by 2029, the market will reach an impressive $5.08 billion, with a compound annual growth rate (CAGR) of 6.2%. This forecasted growth can be ascribed to a multitude of factors such as heightened awareness, the ubiquity of lifestyle-related ailments, innovation in therapies, a growing emphasis on men’s health, the rise of telemedicine, and improved healthcare accessibility. In the forecast period, significant trends will emerge, such as a greater focus on mental and sexual health, the exploration of nutraceuticals and lifestyle interventions, the proliferation of the market in emerging economies, increased joint research initiatives, along with an emphasis on long-term safety and monitoring.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9969&type=smp

What are the Key Market Players in Male Hypogonadism Market and How They’re Evolving?

Major companies operating in the male hypogonadism market include Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Ferring Pharmaceuticals, Finox Biotech AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, IBSA Institut Biochimique SA, Sun Pharmaceutical Industries Limited, Glenmark Pharmaceuticals Limited, Antares Pharma Inc., Zydus Cadila LLC, Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Foresee Pharmaceuticals Co. Ltd., Lipocine Inc., Myovant Sciences Ltd., Sandoz International GmbH, Shionogi & Co. Ltd., TherapeuticsMD Inc., Viking Therapeutics Inc.

What Are the Primary Growth Drivers in the Male Hypogonadism Market?

The rise in infertility is anticipated to fuel the expansion of the male hypogonadism market. Infertility, a state that hampers the reproductive system in males or females, is identified by the failure to achieve pregnancy despite 12 months or more of regular contraceptive-free intercourse. Male hypogonadism could result in reduced sperm production and infertility, thereby potentially contributing to male infertility. Consequently, the escalating incidence of male infertility is predicted to propel the male hypogonadism market’s growth. For instance, the Office for National Statistics, a UK government department, reported in February 2024 that the total fertility rate (TFR) had risen to 1.49 children per woman in 2022, up from 1.55 in 2021. Hence, the surge in infertility rates is accelerating the expansion of the male hypogonadism market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9969&type=smp

What Are the Leading Segments in the Global Male Hypogonadism Industry?

The male hypogonadism market covered in this report is segmented –

1) By Type: Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, Other Types

2) By Drug Delivery: Topical Gels, Injectables, Transdermal Patches, Other Drug Deliveries

3) By Therapy: Testosterone Therapy, Gonadotropin-Releasing Hormone Therapy

Subsegments:

1) By Klinefelter’s Syndrome: 47,XXY Syndrome, Other Variants

2) By Kallmann Syndrome: Isolated Kallmann Syndrome, Syndromic Kallmann Syndrome

3) By Pituitary Disorders: Hypopituitarism, Pituitary Tumors, Other Pituitary Disorders

4) By Other Types: Androgen Insensitivity Syndrome, Testicular Dysgenesis Syndrome, Genetic Mutations And Disorders

What Are the Key Market Trends in the Male Hypogonadism Industry?

There is an increasing trend of product innovations in the male hypogonadism market. To retain their market dominance, businesses in the male hypogonadism field are introducing innovative new products. For example, in June 2022, Tlando, an oral testosterone replacement therapy for male hypogonadism, was introduced by Halozyme, a biotechnology firm based in the United States. Tlando, which is a prescription medication containing testosterone, is the first oral testosterone treatment to receive FDA approval and is intended for use in adult men who have low to no testosterone due to certain health conditions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report

What Is the Regional Outlook for the Male Hypogonadism Market?

North America was the largest region in the male hypogonadism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9969

This Report Delivers Insight On:

1. How big is the male hypogonadism market, and how is it changing globally?

2. Who are the major companies in the male hypogonadism market, and how are they performing?

3. What are the key opportunities and risks in the male hypogonadism market right now?

4. Which products or customer segments are growing the most in the male hypogonadism market?

5. What factors are helping or slowing down the growth of the male hypogonadism market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model